Endoscopy Devices MarketSize, Share & Industry Analysis, 2026-2034By ProductBy ApplicationBy End-useBy Distribution ChannelBy Technology

Endoscopy devices are the instruments, visualization systems and accessories used to examine and treat internal organs and cavities through minimally invasive access, spanning both flexible scopes used in gastrointestinal, pulmonary and urological procedures and rigid scopes used in laparoscopic, arthroscopic and gynecological surgery. The category includes the imaging hardware, such as light sources, cameras and monitors, that renders the procedure visible to the operating team, alongside the hand instruments and energy devices used to complete the intervention. Buyers are hospitals, ambulatory surgery centers and specialty clinics that purchase both capital equipment for procedure rooms and the disposable or reusable instruments consumed with each case.

Between 2025 and 2034 the global endoscopy devices market moves from USD 54.2 billion to USD 97.99 billion, compounding at 6.8% a year. Fifteen years are covered in all, taking in USD 38.5 billion in 2020, USD 51.9 billion in 2024, USD 57.89 billion in 2026 and USD 75.32 billion in 2030.

On the product axis, growth rates run from 4.34% for Operative Devices up to 13.92% for Robot Assisted Endoscopy Devices. Endoscopes carries the volume: USD 22.76 billion and 42% of revenue in 2025, USD 35.28 billion and 36% in 2034. Share moves toward Disposable Endoscopy Devices and Robot Assisted Endoscopy Devices and away from Endoscopes, Endoscopy Visualization Systems and Operative Devices, though no line shrinks in revenue terms.

The application split puts Gastrointestinal (GI) endoscopy first, at USD 18.43 billion and 34% of revenue in 2025, rising to USD 30.38 billion and 31% in 2034. Bronchoscopy grows faster at 12.14% against 5.7%, moving from 7% of revenue to 11% by 2034. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.

North America is the largest region at 36.5% of 2025 revenue, worth USD 19.78 billion and reaching USD 32.34 billion by 2034. Asia Pacific follows at 27%, moving from USD 14.63 billion to USD 31.36 billion, and Middle East and Africa is the smallest at 5.5%. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

Behind these figures sit five regions, five product lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is a triangulation of published figures and category proxies rather than a directly sourced total, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global endoscopy devices market moves from USD 38.5 billion in 2020 to USD 54.2 billion in 2025 and USD 97.99 billion by 2034, the forecast period compounding at 6.8% a year.
• Endoscopes is the largest product line at USD 22.76 billion in 2025, a 42% share, reaching USD 35.28 billion and 36% of revenue by 2034.
• At 13.92%, Robot Assisted Endoscopy Devices grows faster than any other product line, moving from USD 3.25 billion and 6% of revenue in 2025 to USD 10.78 billion and 11% in 2034.
• Scenario range for 2034 runs from USD 88.19 billion in the bear case to USD 109.75 billion in the bull case, against a base-case USD 97.99 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 19.78 billion in 2025 (36.5% of the global total) and USD 32.34 billion by 2034, ahead of Asia Pacific at 27%.
• 88% of North America's base-year revenue comes from the United States alone: USD 17.41 billion in 2025, rising to USD 28.46 billion by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

The global endoscopy devices market is shaped over 2026-2034 by three measurable movements: a change in the product mix, a shift in where revenue sits geographically, and the 6.8% rate carrying the total.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; what changes is which of them captures the revenue added.

Composition shifts on the product axis. 13.92% against 4.34%: that gap, between Robot Assisted Endoscopy Devices and Operative Devices, is the largest on the product axis. Over the forecast period that moves Robot Assisted Endoscopy Devices from 6% of revenue to 11%, and Operative Devices from 16% to 13%. The revenue figures behind that are USD 3.25 billion to USD 10.78 billion and USD 8.67 billion to USD 12.74 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific and Latin America. Asia Pacific moves from 27% of revenue in 2025 to 32% in 2034, worth USD 14.63 billion rising to USD 31.36 billion; Latin America moves from 6% of revenue in 2025 to 6.5% in 2034, worth USD 3.25 billion rising to USD 6.37 billion. Share moves off the others in turn: North America at 36.5% moving to 33%, Europe at 25% moving to 23%, Middle East and Africa at 5.5% moving to 5.5%, each still growing in revenue terms. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

A continuation, not an inflection. The market moves through USD 38.5 billion in 2020, USD 51.9 billion in 2024, USD 54.2 billion in 2025, USD 57.89 billion in 2026, USD 75.32 billion in 2030 and USD 97.99 billion in 2034. The forecast rate of 6.8% sits against 7.08% over the historical period, so the projection extends an observed trend instead of proposing a new one. For a participant that makes planning a question of capturing a share of steady expansion rather than timing a discontinuity, and it is why the product and regional mixes matter more to a forecast than the headline rate does.

Growth is concentrated in Robot Assisted Endoscopy Devices

The 6.8% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the product axis, and where regional growth is concentrated.

What holds the forecast back

What the bull case turns on

The total depends on a single line

USD 19.78 billion of 2025 revenue is generated in North America, 36.5% of the global endoscopy devices market with USD 32.34 billion projected for 2034. It is a dominant region on this axis, first by revenue throughout the period.

Share settles at 33% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight rather than as falling revenue.

The product mix reported at global level applies here, with Endoscopes the largest line at 42% of 2025 revenue and Robot Assisted Endoscopy Devices the fastest-growing at 13.92%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The largest single market in North America is the United States, at USD 17.41 billion in 2025 and USD 28.46 billion in 2034. Carrying 88% of the region in the base year, it sets North America's direction rather than contributing to it. The region itself runs USD 19.78 billion to USD 32.34 billion over the same period, and this is the market carrying the country-level detail in the full report.

the United States buys along the same lines as the market globally; Endoscopes first at 42% of 2025 revenue and 36% in 2034, Robot Assisted Endoscopy Devices fastest at 13.92% on a share moving from 6% to 11%. Its 88% weight in North America means those movements carry straight into the regional totals. The United States carries its own product breakdown in the full report.

The Food and Drug Administration governs endoscopy devices as medical devices, with most such instruments falling into an intermediate risk classification that requires manufacturers to demonstrate substantial equivalence to a legally marketed device before commercial distribution. Establishments must operate under the agency's quality system regulation, covering design controls, manufacturing controls, and corrective action processes, and must comply with harmonized international quality management standards for medical device manufacturing. Labeling must clearly state intended use, reprocessing and sterilization instructions, and applicable warnings. Post-market obligations include adverse event reporting and registration of manufacturing establishments and listed devices with the agency before a unit may reach a hospital or clinic.

Competition in the United States runs between the suppliers this study tracks: Olympus Corporation, Ethicon Endo-surgery, LLC., FUJIFILM Holdings Corporation, Stryker Corporation, Boston Scientific Corporation, Karl Storz GmbH & Co. KG, Smith & Nephew Inc., Richard Wolf GmbH, Medtronic Plc (Covidien), PENTAX Medical, Machida Endoscope Co., Ltd., Ambu A/S, CONMED Corporation, Intuitive Surgical, Inc. and Cook Medical. Endoscopes, at 42% of 2025 revenue, is where the volume sits, and Robot Assisted Endoscopy Devices, growing at 13.92%, is where position changes hands over the forecast period. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 2.37 billion in 2025, rising to USD 3.88 billion by 2034; 4.37% of global revenue and 12% of North America. It is reported separately from the United States across every segmentation axis in the full report.

Europe holds 25% of the global endoscopy devices market in 2025, worth USD 13.55 billion and reaches USD 22.54 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 23%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The product mix reported at global level applies here, with Endoscopes the largest line at 42% of 2025 revenue and Robot Assisted Endoscopy Devices the fastest-growing at 13.92%. Europe is reported axis by axis and country by country in the full study.

USD 3.79 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 6.31 billion by 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 13.55 billion in 2025 and USD 22.54 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Endoscopes at 42% of 2025 revenue, easing to 36% by 2034, and the fastest is Robot Assisted Endoscopy Devices at 13.92%, from 6% to 11%. Its 28% weight in Europe means those movements carry straight into the regional totals. Germany carries its own product breakdown in the full report.

Under the European Union's Medical Device Regulation framework, endoscopy devices are classified according to risk and invasiveness, with reusable and single-use scopes typically requiring assessment by a Notified Body before a CE mark can be affixed. German manufacturers and distributors must maintain technical documentation demonstrating conformity with essential safety and performance requirements, apply a quality management system aligned with the relevant harmonized standard, and register with the national competent authority alongside the European database for medical devices. Labelling must be provided in German, stating intended purpose, reprocessing instructions, and any warnings. Economic operators bear post-market surveillance and vigilance reporting duties once a device is placed on the market.

Olympus Corporation, Ethicon Endo-surgery, LLC., FUJIFILM Holdings Corporation, Stryker Corporation, Boston Scientific Corporation, Karl Storz GmbH & Co. KG, Smith & Nephew Inc., Richard Wolf GmbH, Medtronic Plc (Covidien), PENTAX Medical, Machida Endoscope Co., Ltd., Ambu A/S, CONMED Corporation, Intuitive Surgical, Inc. and Cook Medical are the suppliers covered in Germany. Volume sits in Endoscopes at 42% of 2025 revenue; movement sits in Robot Assisted Endoscopy Devices at 13.92% growth.

The United Kingdom is sized at USD 3.25 billion in 2025, rising to USD 5.41 billion by 2034; 6% of global revenue and 24% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 2.44 billion in 2025, rising to USD 4.06 billion by 2034; 4.5% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

In Asia Pacific, 27% of global revenue puts 2025 at USD 14.63 billion rising to USD 31.36 billion in 2034. It is a leading region on this axis, second by revenue throughout the period.

Share climbs to 32% by 2034, so the region grows faster than the market's 6.8% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The product mix reported at global level applies here, with Endoscopes the largest line at 42% of 2025 revenue and Robot Assisted Endoscopy Devices the fastest-growing at 13.92%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

USD 4.97 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 10.66 billion by 2034. Its 34% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 14.63 billion in 2025 and USD 31.36 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

China buys along the same lines as the market globally; Endoscopes first at 42% of 2025 revenue and 36% in 2034, Robot Assisted Endoscopy Devices fastest at 13.92% on a share moving from 6% to 11%. Because the country carries 34% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Revenue by product for China is reported separately in the full report.

In China, endoscopy devices fall under the oversight of the National Medical Products Administration, which classifies instruments by risk and requires registration before sale, with higher-risk reusable scopes generally needing clinical evaluation data and manufacturing site inspection. Manufacturers, whether domestic or foreign, must appoint a local agent, compile a technical dossier demonstrating safety and performance, and conform to national medical device quality management requirements modeled on international standards. Labelling and instructions must appear in Chinese, describing intended use, reprocessing steps, and contraindications. Once registered, holders remain subject to ongoing adverse event monitoring and periodic reassessment obligations administered by provincial and national authorities.

In China the field is Olympus Corporation, Ethicon Endo-surgery, LLC., FUJIFILM Holdings Corporation, Stryker Corporation, Boston Scientific Corporation, Karl Storz GmbH & Co. KG, Smith & Nephew Inc., Richard Wolf GmbH, Medtronic Plc (Covidien), PENTAX Medical, Machida Endoscope Co., Ltd., Ambu A/S, CONMED Corporation, Intuitive Surgical, Inc. and Cook Medical. The commercially relevant division is 42% of 2025 revenue in Endoscopes, where the volume is, against 13.92% growth in Robot Assisted Endoscopy Devices, where share moves.

Within Asia Pacific, Japan accounts for 26% of regional revenue and 7.01% of the global total, worth USD 3.8 billion in 2025 and USD 8.15 billion by 2034.

India is sized at USD 2.05 billion in 2025, rising to USD 4.39 billion by 2034; 3.78% of global revenue and 14% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

In Latin America, 6% of global revenue puts 2025 at USD 3.25 billion on the way to USD 6.37 billion by 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 6.5%, at a pace above the 6.8% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Within the region the product split tracks the global one; 42% of 2025 revenue in Endoscopes, fastest growth of 13.92% in Robot Assisted Endoscopy Devices. The full report breaks Latin America out along every axis and by country.

Brazil is the largest market within Latin America, generating USD 1.63 billion in 2025 and projected to reach USD 3.19 billion by 2034. 50% of the region in the base year makes it the largest market here without making it the region. Set against USD 3.25 billion and USD 6.37 billion for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in Brazil follows the product mix reported at global level: Endoscopes is the largest line at 42% of 2025 revenue, moving to 36% by 2034, while Robot Assisted Endoscopy Devices grows fastest at 13.92% and takes its share from 6% to 11%. With 50% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-product revenue for Brazil appears on its own in the full report.

In Brazil, the National Health Surveillance Agency regulates endoscopy devices, classifying them by risk and requiring registration or notification before a product may be marketed, with more invasive or reusable scopes subject to fuller technical review. Manufacturers must demonstrate conformity with the agency's good manufacturing practice requirements, often verified through facility inspection, and align quality systems with recognized international medical device standards. Labelling and instructions for use must be presented in Portuguese, covering intended purpose, reprocessing protocols, and precautions. Local representation is required for foreign manufacturers, and registration holders must maintain post-market vigilance reporting to the agency once devices are in clinical use.

Olympus Corporation, Ethicon Endo-surgery, LLC., FUJIFILM Holdings Corporation, Stryker Corporation, Boston Scientific Corporation, Karl Storz GmbH & Co. KG, Smith & Nephew Inc., Richard Wolf GmbH, Medtronic Plc (Covidien), PENTAX Medical, Machida Endoscope Co., Ltd., Ambu A/S, CONMED Corporation, Intuitive Surgical, Inc. and Cook Medical are the suppliers covered in Brazil. Endoscopes, at 42% of 2025 revenue, is where the volume sits, and Robot Assisted Endoscopy Devices, growing at 13.92%, is where position changes hands over the forecast period.

1.81% of global revenue is generated in Mexico; USD 0.98 billion in 2025, reaching USD 1.91 billion in 2034, and 30% of Latin America.

5.5% of the global endoscopy devices market sits in Middle East and Africa in 2025, worth USD 2.98 billion with USD 5.39 billion projected for 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Its share moves to 5.5% by 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

The product mix reported at global level applies here, with Endoscopes the largest line at 42% of 2025 revenue and Robot Assisted Endoscopy Devices the fastest-growing at 13.92%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 1.04 billion in 2025 and USD 1.89 billion in 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Set against USD 2.98 billion and USD 5.39 billion for the region, it is why this market rather than a smaller one is the one reported in full.

The product pattern in Saudi Arabia is the global one: 42% of 2025 revenue in Endoscopes, 36% by 2034, against 13.92% growth in Robot Assisted Endoscopy Devices taking it from 6% to 11%. Its 35% weight in Middle East and Africa means those movements carry straight into the regional totals. Revenue by product for Saudi Arabia is reported separately in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority oversees endoscopy devices through its medical device registration system, classifying instruments by risk and requiring listing on the national registry before distribution, generally following global harmonization task force classification principles. Manufacturers must appoint an authorized representative established in the Kingdom, submit technical documentation demonstrating conformity with recognized international safety and performance standards, and hold valid quality management system certification. Labelling must include Arabic language instructions, intended use, reprocessing guidance, and warnings appropriate for clinical settings. Ongoing obligations include incident reporting and maintaining traceability records to support market surveillance activities across the region.

Competition in Saudi Arabia runs between the suppliers this study tracks: Olympus Corporation, Ethicon Endo-surgery, LLC., FUJIFILM Holdings Corporation, Stryker Corporation, Boston Scientific Corporation, Karl Storz GmbH & Co. KG, Smith & Nephew Inc., Richard Wolf GmbH, Medtronic Plc (Covidien), PENTAX Medical, Machida Endoscope Co., Ltd., Ambu A/S, CONMED Corporation, Intuitive Surgical, Inc. and Cook Medical. Two different problems sit on the same axis: holding Endoscopes at 42% of 2025 revenue, and taking Robot Assisted Endoscopy Devices while it grows at 13.92%.

South Africa is sized at USD 0.6 billion in 2025, rising to USD 1.08 billion by 2034; 1.11% of global revenue and 20% of Middle East and Africa. It is reported separately from Saudi Arabia across every segmentation axis in the full report.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product, application, end-use, distribution channel, technology, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.